Newspaper logo  
 
 
Local Gov’t Stories, Events

08.15 RIDE FOR THE OVERRIDE

Ref. : Civic Events

Ref. : Arts & Education Events

Ref. : Public Service Notices

Travel
Books, Films, Arts & Education

12.08 How Do American Students Compare to Their International Peers?

12.07 What America Can Learn About Smart Schools in Other Countries

Letters

Ref. : Letters to the editor

Health Care & Environment

12.08 Portland's Answer to Climate Denial? Local Action

12.08 Meet the High-Tech Buses of Tomorrow [perhaps smaller, non-polluting buses can come twice as often, too]

12.08 Mapping the Inundation of New York City

12.08 Leonardo DiCaprio meets Trump as climate sceptic appointed

12.08 Trump picks climate change sceptic Scott Pruitt to lead EPA

12.07 Trump’s Infrastructure Plan Is a Full-on Privatization Assault

12.07 Trump advisors aim to privatize oil-rich Indian reservations [drill, pump, burn, breathe, die]

12.07 Thousands of snow geese die in Montana after landing on contaminated water

12.07 Five west African countries ban 'dirty diesel' from Europe

12.07 London mayor to double funding to tackle air pollution

12.07 Donald Trump supports 'clean coal' – but does it really have a future?

12.07 Google, Apple, Facebook race towards 100% renewable energy target

12.07 Google Says It Will Run Entirely on Renewable Energy in 2017

12.05 Trump's pick for key health post known for punitive Medicaid plan

12.05 Asleep at the Wheel: German Leaders at Odds with Industry over Electric Cars

12.05 Dakota Access Pipeline Permit Denied

News Media Matters

Daily: FAIR Blog
The Daily Howler

US Politics, Policy & 'Culture'

12.07 Democrats Need to Embrace Progressivism or Else Move Out of the Way

12.07 Forget Air Force One, Pentagon Wastes Billions and Billions Every Month

12.06 Why Does Donald Trump Lie About Voter Fraud?

12.06 FIGHTING FOR THE POOR UNDER TRUMP

12.06 Want to Bring Back Jobs, Mr. President-Elect? Call Elon Musk [dare to be smart]

12.06 Jamie Raskin Has a Fierce, Funny Message for Dispirited Democrats

12.06 Career of Trump's Top Ethics Lawyer Marred by Questionable Ethics

Justice Matters

12.07 President Obama’s Last Chance to Show Mercy

12.06 Did Trump’s Son-In-Law Finance Israeli Extremists and Illegal Settlements?

High Crimes?

12.05 Sea Shepherd activists set sail for Antarctic to battle Japanese whalers

Economics, Crony Capitalism

12.08 Who Won the 'Make the Most Meaningless Thomas Friedman Graph' Contest? [humor with graphs, because we need some!]

12.08 In the UK, Pfizer and a partner hiked anti-epilepsy drug price 2600% overnight [bring out the guillotine]

12.08 “We’ll Look at Everything”: More Thoughts on Trump’s $1 Trillion Infrastructure Plan

12.04 TRUMP SETS PRIVATE PRISONS FREE

12.04 WHY TRUMP SHOULD SPEND OTHER PEOPLE’S MONEY

International

12.08 After Choi-gate

12.08 France's honest tax system crusader convicted for hiding millions of euros

12.06 FAIR’s big play: Onetime fringe group hopes to drive Donald Trump’s immigration policy

12.06 Brazil's Senate president ousted over embezzlement charges

12.06 Brazil grapples with lynch mob epidemic: 'A good criminal is a dead criminal'

12.06 Before the article 50 court battle, there was May v Merkel

12.06 Austrians celebrate far right defeat: 'the first good election result this year'

12.05 Euro falls to 20-month low after Italy government's referendum defeat

12.05 'A storm is gathering on the horizon': Chinese scholars fret about Trump

We are a non-profit Internet-only newspaper publication founded in 1973. Your donation is essential to our survival.

You can also mail a check to:
Baltimore News Network, Inc.
P.O. Box 42581
Baltimore, MD 21284-2581
Google
This site Web
  Big Pharma Wins Big in Health Care Reform

COMMENTARY:

Big Pharma Wins Big in Health Care Reform

by James Ridgeway
First published in his blog Unsilent Generation yesterday, 22 March 2010
To a large extent, the “debate” over health care was a show debate, an extended round of Washington smoke and mirrors. The administration early on cut its deal with Big Pharma, and pretty much stuck to it throughout the process.

The Republicans look a sour lot this morning, but the pharmaceutical industry, which helps foot the campaign bills of a sizeable chunk of members of both parties, is delighted with the legislation, and with its Democratic friends in the White House and on the Hill.

Members of Congress in both parties generally have lined up behind the insurance and pharmaceutical industries from the get go. So it should come as no surprise that the Democrats, who long ago gave up any pretence of opposing corporate power, found a way to accomodate the pharmaceutical companies on the way to its tepid reform. To a large extent, the “debate” over health care was a show debate, an extended round of Washington smoke and mirrors. The administration early on cut its deal with Big Pharma, and pretty much stuck to it throughout the process.

In fact, the Dems actually made the drugsters look good, celebrating the industry’s generous “concessions” and “discounts” while ensuring that no real threat to Big Pharma’s profits would make their way into the final bill.

The industry’s main goal from the very beginning has been to fend off any government power to negotiate or seriously regulate drug prices–and this they did.

Big Pharma’s second big win was to prevent any measure that would have opened the way for American consumers to buy less expensive drugs abroad, especially from Canada.

At the same time, the supposed give-backs by the drug industry are projected to more than pay for themselves. The much-lauded discounts on brand name drugs for seniors in the Medicare prescription drug program, for example, are good for Big Pharma because they discourage oldsters from switching to generics.

And more insured people simply mean more money coming into the coffers, for Big Pharma as well as for the insurance industry.

Confirmation of the industry analysis came early in the day from the stock market, where drug stocks initially remained level; there certainly was no rush to dump shares, which is what would be expected if the bill actually represented any threat to profits. And by 1 p, EST, CNN Money was reporting a rally in health care stocks.

“I was unable to find anything in there that would cause me to have anxiety if I were a shareholder in a pharmaceutical company,” Ira Loss, a senior health-care analyst at the research firm Washington Analysis, told Dow Jones. According to the ticker story:

Billy Tauzin, who led the industry’s negotiations on health care with lawmakers, said overall drug makers fare well. “While we’re not totally happy,” Tauzin began, “we generally feel like it tracks with our principles.”

Sanofi-Aventis SA (SNY) Chief Executive Christopher Viehbacher said in an interview that the impact of the legislation will be neutral to slightly negative “but better for the industry than if healthcare reform didn’t pass.”

Tauzin, head of the Pharmaceutical Research and Manufacturers of America or PhRMA, and Viehbacher said getting protection for brand-name biologics is among the important provisions for the industry. Drug makers pushed hard to get 12 years of exclusive market protection while the White House and some lawmakers wanted to lower the protection to seven years.

Despite fees and rebates imposed by the legislation, “analysts say drug makers will end up recouping those costs through new customers: The bill would provide insurance coverage to an additional 32 million Americans.” The Dow Jones story continues:

Chalk up another good round for Pharma and Biotech in health care reform,” began a note to clients Friday from Concept Capital, a research firm.Ken Tsuboi, co-manager of the Allianz RCM Wellness Fund, sees the impact of bill, and its $90 billion in concessions over 10 years, as relatively minor in an industry that has annual global sales of about $750 billion, with about $300 billion in the U.S., and margins close to 30%.”I think that it is actually a pretty good deal for Pharma,” Tsuboi said.

The GOP, which purports to be the party of big business, ought to be applauding at least these portions of the health care reform—and perhaps when the cameras go away, some of them will quit bitching and count their blessings. As for the obnoxious Tea Party gang, if they start threatening the real power in this country, which is vested in corporations, they may well find themselves whipped and isolated.


Born in 1936, James Ridgeway has been reporting on politics for more than 45 years. He is currently Senior Washington Correspondent for Mother Jones, and recently wrote a blog on the 2008 presidential election for the Guardian online. He previously served as Washington Correspondent for the Village Voice; wrote for Ramparts and The New Republic; and founded and edited two independent newsletters, Hard Times and The Elements.

Ridgeway is the author of 16 books, including The Five Unanswered Questions About 9/11, It’s All for Sale: The Control of Global Resources, and Blood in the Face: The Ku Klux Klan, Aryan Nations, Nazi Skinheads, and the Rise of a New White Culture. He co-directed a companion film to Blood in the Face and a second documentary film, Feed, and has co-produced web videos for GuardianFilms.

Additional information and samples of James Ridgeway’s work can be found at JamesRidgeway.net and at his newest web site, Solitary Watch.

This article is republished in the Baltimore Chronicle with permission of the author.



Copyright © 2010 The Baltimore News Network. All rights reserved.

Republication or redistribution of Baltimore Chronicle content is expressly prohibited without their prior written consent.

Baltimore News Network, Inc., sponsor of this web site, is a nonprofit organization and does not make political endorsements. The opinions expressed in stories posted on this web site are the authors' own.

This story was published on March 23, 2010.
 



Public Service Ads:
Verifiable Voting in Maryland